Angiotech announces results for the third quarter ended September 30, 2007



    VANCOUVER, Nov. 1 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced its full financial results for the third quarter ended September 30,
2007.
    "During this past quarter, there has been significant progress made on
several key products nearing commercial launch, including FDA approval of the
HemoStream(TM) chronic dialysis catheter, FDA clearance and CE Mark approvals
for a variety of Quill(TM) SRS products, and positive results from our pivotal
CVC study," said Dr. William Hunter, President and CEO of Angiotech. "After
completing the build out of our U.S. surgical sales force in the third
quarter, we were in an excellent position to showcase our Quill(TM) SRS
product line at the recent Annual Meeting of the American Society of Plastic
Surgeons (ASPS), and we were pleased to find that the response from physicians
far exceeded expectations."
    On October 19, 2007, immediately following the release of BSC's third
quarter 2007 financial results, Angiotech released preliminary results for the
third quarter of 2007 and updated its 2007 outlook for royalty revenue,
product sales, and Adjusted EBITDA.

    Financial Update:

    The following includes additional financial updates subsequent to the
press release from October 19, 2007:

    
    -  GAAP net loss from continuing operations and net loss per share from
       continuing operations were ($10.8) million and ($0.13), respectively.
       Our GAAP results reflect several non-cash, non-recurring items.

    -  Adjusted net loss from continuing operations and adjusted net loss per
       share from continuing operations were ($3.1) million and ($0.04),
       respectively.

    -  Our revised outlook for 2007 adjusted net income per share is $0.07
       to $0.10.
    

    We caution that the information contained in the press release concerning
our revised outlook for 2007 is forward-looking and, accordingly, actual
results may differ materially.

    Financial Information
    ---------------------

    This press release contains the condensed financial statements derived
from the unaudited consolidated interim financial statements for the three-
and nine-month periods ended September 30, 2007, and audited consolidated
financial statements for the year ended December 31, 2006. Full unaudited
consolidated interim financial statements and Management's Discussion and
Analysis for the three- and nine month periods ended September 30, 2007, will
be filed with the relevant regulatory agencies, as well as posted on our
website at www.angiotech.com.
    We completed the acquisition of the operations of American Medical
Instruments Holdings, Inc. ("AMI") on March 23, 2006. Because of the timing of
the AMI acquisition, our operating results for the nine month period ended
September 30, 2006 include AMI's results of operations from the period of
March 24, 2006 to September 30, 2006, as compared to the current nine month
period which reflects combined results from the period of January 1, 2007 to
September 30, 2007. As a result, our results for the nine months ended
September 30, 2007 do not reflect a comparable operating period as compared to
the nine months ended September 30, 2006.
    Amounts, unless specified otherwise, are expressed in U.S. dollars.
Financial results are reported under GAAP unless otherwise noted. All per
share amounts are stated on a diluted basis unless otherwise noted.

    Use of Certain Non GAAP Financial Measures
    ------------------------------------------

    Certain financial results presented in this press release include
non-GAAP measures that exclude certain items. Adjusted net income from
continuing operations, adjusted net income per share from continuing
operations and adjusted earnings before interest, taxes, depreciation and
amortization ("Adjusted EBITDA") exclude certain non-cash and non-recurring
items such as acquisition related amortization charges, acquired in-process
research and development relating to license agreements and acquisitions,
stock-based compensation expense, foreign exchange gains or losses relating to
translation of foreign currency cash and investment balances and other
non-recurring items. Adjusted net income from continuing operations, adjusted
net income per share from continuing operations and Adjusted EBITDA also
exclude litigation expenses related to defending intellectual property claims.
Revenue, as adjusted, excludes non-recurring, non-operating revenue derived
from license agreements and other license revenue, net of license fees due to
licensors and excludes amounts accrued for costs incurred, and potential
future costs, related to our offer to accept returns of Contour Threads brand
product as part of our announced brand name consolidation and discontinuation.
Adjusted net income from continuing operations, adjusted net income per share
from continuing operations, revenue from continuing operations, as adjusted
and Adjusted EBITDA do not have any standardized meaning prescribed by GAAP
and therefore may not be comparable to similar measures presented by other
issuers. Management uses these non-GAAP or adjusted operating measures to
establish operational goals, and believes that these measures may assist
investors in analyzing the underlying trends in our business over time.
Investors should consider these non-GAAP measures in addition to, not as a
substitute for, or as superior to, financial reporting measures prepared in
accordance with GAAP. We have provided a reconciliation of these measures to
GAAP in the attached tables.
    The financial outlook referred to above presents certain forward-looking,
non-GAAP financial information for which at this time there is no calculable
comparable GAAP measure. As a result, such non-GAAP financial information
cannot be quantitatively reconciled to comparable GAAP financial information.
Specifically, the adjusted net income per share amounts referred to above
exclude estimates of certain expenses that are inherently unpredictable or
subject to significant fluctuation for reasons unrelated to our business
performance, including stock-based compensation expenses, certain litigation
expenses and foreign exchange gains or losses.

    Conference Call Information
    ---------------------------

    A conference call to discuss these financial results will be held today,
Thursday, November 1, 2007 at 8:00 AM PT (11:00 AM ET).

    Dial-in information:
    North America (toll free): (800) 901-5213
    International: (617) 786-2962
    Enter passcode: 75137732

    A replay archive of the conference call will be available until November
8, 2007 by calling (888) 286-8010 (in North America) or (617) 801-6888
(International) and entering Access Code 15190735.
    A live webcast will be available to all interested parties through the
Investors section of Angiotech's website: www.angiotech.com.

    
                       ANGIOTECH PHARMACEUTICALS, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                 (Unaudited)


    (in thousands of
    U.S.$, except
    share and per          Three months ended         Three months ended
    share data)            September 30, 2007         September 30, 2006
    -------------------------------------------------------------------------
                       Reported  Adjust- Adjusted Reported  Adjust- Adjusted
                                  ments                      ments
    REVENUE
    Royalty revenue      26,622            26,622   43,709            43,709
    Product sales, net   41,351            41,351   42,509            42,509
    License fees             53     (53)a       -       53     (53)a       -
    -------------------------------------------------------------------------
                         68,026     (53)   67,973   86,271     (53)   86,218
    -------------------------------------------------------------------------
    EXPENSES
    License and royalty
     fees                 4,527             4,527    6,933             6,933
    Cost of products
     sold                23,384    (253)b  23,131   20,996            20,996
    Research and
     development         13,188    (542)c  12,646   11,740    (596)c  11,144
    Selling, general
     and administrative  24,715  (3,173)d  21,542   20,953  (2,817)d  18,136
    Depreciation and
     amortization         8,119  (7,244)e     875    9,171  (8,215)e     956
    -------------------------------------------------------------------------
                         73,933 (11,212)   62,721   69,793 (11,628)   58,165
    -------------------------------------------------------------------------
    Operating (loss)
     income              (5,907) 11,159     5,252   16,478  11,575    28,053
    -------------------------------------------------------------------------
    Other income
     (expenses):
    Foreign exchange
     gain (loss)           (110)    110 f       -     (528)    528 f       -
    Investment and
     other income         2,073             2,073      977    (148)h     829
    Interest expense
     on long-term debt  (13,280)    558 g (12,722) (11,325)    645 g (10,680)
    -------------------------------------------------------------------------
                        (11,317)    668   (10,649) (10,876)  1,025    (9,851)
    -------------------------------------------------------------------------
    Income (loss) from
     continuing
     operations before
     income taxes       (17,224) 11,826    (5,397)   5,602  12,600    18,202
    Income tax expense
     (recovery)          (6,392)  4,139 i  (2,253)  (1,802)  3,566 i   1,764
    -------------------------------------------------------------------------
    Net (loss) income
     from continuing
     operations         (10,832)  7,688    (3,144)   7,404   9,034    16,438
    -------------------------------------------------------------------------
    Net loss from
     discontinued
     operations, net
     of income taxes     (1,156)  1,156         -     (478)    478         -
    -------------------------------------------------------------------------
    Net (loss) income
     for the period     (11,988)  8,844    (3,144)   6,926   9,512    16,438
    -------------------------------------------------------------------------

    Basic net (loss)
     income per common
     share from
     continuing
     operations           (0.13)            (0.04)    0.09              0.19
    Diluted net (loss)
     income per common
     share from
     continuing
     operations           (0.13)            (0.04)    0.09              0.19
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Weighted average
     shares outstanding
     (000's) - basic     85,014            85,014   84,832            84,832
    Weighted average
     shares outstanding
     (000's) - diluted   85,432            85,432   85,463            85,463
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    a.  Non-recurring, non-operating license revenue, net of license fees
        due to licensors.
    b.  Change in estimate of accounting for excess and obsolete
    c.  Stock-based compensation expense.
    d.  Selling, general and administrative adjustments:
        ---------------------------------------------------------------------
                                                 Three months   Three months
                                                ended Sept 30, ended Sept 30,
                                                     2007           2006
                                                -----------------------------
         Stock-based compensation expense               (811)          (924)
         Termination and reorganization costs
          related to closure of the Syracuse
          facility.                                   (1,454)             -
         Litigation expenses relating to
          defending intellectual property claims        (908)        (1,893)
    	    --------------------------------------------------------------------
         Total                                        (3,173)        (2,817)
        ---------------------------------------------------------------------
    e.  Amortization of acquisition related intangible assets and medical
        technologies.
    f.  Foreign exchange fluctuations on foreign currency net monetary
        assets.
    g.  Amortization of deferred financing costs.
    h.  Gain on sale related to disposition of Neodisc technology rights to
        NuVasive.
    i.  Tax effects of adjustments a. through h. for the period. Comparative
        for 2006 also includes non-recurring Quebec retroactive tax
        adjustment of $8.7 million.



                       ANGIOTECH PHARMACEUTICALS, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                 (Unaudited)

    (in thousands of
     U.S.$, except
     share and per          Nine months ended          Nine months ended
     share data)           September 30, 2007  	  September 30, 2006
    -------------------------------------------------------------------------
                       Reported  Adjust- Adjusted Reported  Adjust- Adjusted
                                  ments                      ments
    REVENUE
    Royalty revenue      89,500            89,500  127,779           127,779
    Product sales, net  126,258   2,980 a 129,238   93,864            93,864
    License fees            577    (577)b       -      179    (179)b       -
    -------------------------------------------------------------------------

                        216,335   2,403   218,738  221,822    (179)  221,643
    -------------------------------------------------------------------------
    EXPENSES
    License and royalty
     fees                14,235            14,235   19,496            19,496
    Cost of products
     sold                71,261   (1980)c  69,281   45,663            45,663
    Research and
     development         40,407  (4,432)d  35,975   33,228  (1,990)d  31,238
    Selling, general
     and administrative  72,532 (13,194)e  59,338   54,505 (11,033)e  43,472
    Depreciation and
     amortization        24,603 (21,978)f   2,625   21,726 (19,391)f   2,335
    In-process research
     and development      8,000  (8,000)g       -    1,042  (1,042)h       -
    -------------------------------------------------------------------------
                        231,038 (49,584)  181,454  175,660 (33,456)  142,204
    -------------------------------------------------------------------------
    Operating (loss)
     income             (14,703) 51,987    37,284   46,162  33,277    79,439
    -------------------------------------------------------------------------
    Other income
     (expenses):
    Foreign exchange
     gain(loss)            (514)    514 i       -    1,778  (1,778)i       -
    Investment and
     other income         9,881  (5,577)j   4,304    5,494    (833)k   4,661
    Interest expense
     on long-term debt  (38,975)  1,684 l (37,291) (23,611)  1,320 l (22,291)
    Loss on
     sale/write-down
     of investments      (8,157)  8,157 m       -     (413)    413 n       -
    -------------------------------------------------------------------------
                        (37,765)  4,778   (32,987) (16,752)   (878)  (17,630)
    -------------------------------------------------------------------------
    Income (loss) from
     continuing
     operations
     before income
     taxes and
     cumulative effect
     of change in
     accounting         (52,468) 56,765     4,297   29,410  32,399    61,809
    Income tax expense
     (recovery)         (21,331) 14,440 o  (6,891)  12,256   1,053 o  13,309
    -------------------------------------------------------------------------
    Income (loss) from
     continuing
     operations before
     cumulative effect
     of change in
     accounting         (31,137) 42,325    11,188   17,154  31,346    48,500
    -------------------------------------------------------------------------
    Net loss from
     discontinued
     operations, net of
     income taxes        (6,947)  6,947         -   (1,265)  1,265         -
    -------------------------------------------------------------------------
    Cumulative effect
     of change in
     accounting                                        399    (399)        -
    -------------------------------------------------------------------------
    Net (loss) income
     for the period     (38,084) 49,272    11,188   16,288  32,212    48,500
    -------------------------------------------------------------------------

    Basic net (loss)
     income per common
     share from
     continuing
     operations           (0.37)             0.13     0.20              0.57
    Diluted net (loss)
     income per common
     share from
     continuing
     operations           (0.36)             0.13     0.20              0.57
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Weighted average
     shares outstanding
     (000's) - basic     85,010            85,010   84,674            84,674
    Weighted average
     shares outstanding
     (000's) - diluted   85,477            85,477   85,484            85,484
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    a.  Amounts accrued for costs incurred, and potential future costs,
        related to our offer to accept returns of Contour Threads brand
        product as part of a brand name consolidation and discontinuation
        initiative.
    b.  Non-recurring, non-operating revenue as derived from license
        agreements with Histogenics Corporation ($0.4 million in 2007) and
        other license revenue, net of license fees due to licensors.
    c.  Change in estimate of accounting for excess and obsolete inventory
        resulting from the alignment during the third quarter of 2007 of
        inventory policies across our various manufacturing operations, and
        non-recurring supply / distribution agreement termination costs.
    d.  Research and development adjustments:
        ---------------------------------------------------------------------
                                                 Nine months    Nine months
                                                ended Sept 30, ended Sept 30,
                                                     2007           2006
                                                -----------------------------
         Stock-based compensation                     (1,515)        (1,990)
         License fees due to licensors related
          to non-recurring license revenue              (419)             -
         Termination and reorganization costs
          related to the integration of AMI             (849)             -
         Non-recurring supply / distribution
          agreement termination costs                   (899)             -
         Non-recurring in-process research and
          development expense relating to the
          signing of a technology and
          intellectual property license
          agreement with an inventor                    (750)             -
        ---------------------------------------------------------------------
         Total                                        (4,432)        (1,990)
        ---------------------------------------------------------------------

    e.  Selling, general and administrative adjustments:
        ---------------------------------------------------------------------
                                                 Nine months    Nine months
                                                ended Sept 30, ended Sept 30,
                                                     2007           2006
                                                -----------------------------
         Stock-based compensation                     (2,203)        (2,810)
         Termination and reorganization costs
          related to the integration of AMI and
          the closure of the Syracuse facility        (4,839)             -
         Litigation expenses relating to
          defending intellectual property claims      (5,902)        (8,223)
         Non-recurring supply / distribution
          agreement termination costs                   (250)             -
        ---------------------------------------------------------------------
         Total                                       (13,194)       (11,033)
        ---------------------------------------------------------------------

    f.  Amortization of acquisition related intangible assets and medical
        technologies.
    g.  Non-recurring in-process research and development expense relating to
        payments to CombinatorX Inc. and Rex Medical Inc.
    h.  Non-recurring in-process research and development expense, relating
        primarily to a $1.0 million payment due under license agreement with
        Poly-Med, Inc.
    i.  Foreign exchange fluctuations on foreign currency net monetary
        assets.
    j.  Write off of uncollectible tax receivable and write off of certain
        capitalized costs, net of gain realized on recovery of investments.
    k.  Gain on sale of Palo Alto building - assets held for sale and gain on
        sale related to disposition of Neodisc technology rights to NuVasive.
    l.  Amortization of deferred financing costs.
    m.  Net impact of loss and gain on redemption of investments of common
        share holdings in Orthovita Inc. and NuVasive, Inc., respectively.
    n.  Loss on redemption of investments.
    o.  Tax effects of adjustments a. through n. for the period, including
        the reversal of tax reserves previously booked. Comparative for 2006
        also includes non-recurring Quebec retroactive tax adjustment of
        $8.7 million



                       ANGIOTECH PHARMACEUTICALS, INC.
                       CALCULATION OF ADJUSTED EBITDA
                                 (Unaudited)

                                    Three months ended     Nine months ended
                                        September 30,          September 30,
    (in thousands of U.S.$)            2007       2006       2007       2006
    -------------------------------------------------------------------------
    Net income on a GAAP basis      (11,988)     6,926    (38,084)    16,288
    Interest expense on long-term
     debt                            13,281     11,325     38,976     23,611
    Income tax (recovery) expense    (7,055)    (2,101)   (25,885)    11,866
    Depreciation and amortization     9,228     10,554     28,003     24,392
    -------------------------------------------------------------------------
    EBITDA                            3,466     26,704      3,010     76,157
    -------------------------------------------------------------------------
    Adjustments:
      Net loss from discontinued
       operations, excluding
       depreciation, amortization
       and income tax expense
       included above                 1,743        613     11,122      1,255
      In-process research and
       development                        -          -      8,000      1,042
      Non-recurring research and
       development costs                  -          -        750          -
      Non-recurring revenue, net
       of license fees                  (54)       (53)      (160)      (179)
      Stock-based compensation        1,353      1,520      3,717      4,800
      Litigation expenses               908      1,893      5,902      8,223
      Foreign exchange loss (gain)      110        528        514     (1,778)
      Investment and other income    (2,073)      (829)    (4,304)    (4,661)
      Severance/restructuring costs   1,454                 5,438
      Supply/distribution agreement
       termination costs                                    2,199
      E&O inventory adjustment          253                 1,180
      Contour threads returns                               2,980
      Write-off of capitalized costs                          280
      Write-off of uncollectible tax
       receivable                                           2,250
      Gain on sale of sale of
       intangible assets                          (148)                 (148)
      Gain on sale of Palo Alto
       building                                                         (685)
      Gain realized on recovery of
       investment                                          (7,510)    (1,064)
      Accrued interest income                                (597)
      Net loss on redemption of
       investments                                          8,157      1,477
      Cumulative effect of change
       in accounting policy                                             (399)
    -------------------------------------------------------------------------
    Adjusted EBITDA                   7,160     30,228     42,928     84,040
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



                       ANGIOTECH PHARMACEUTICALS, INC.
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (Unaudited)

    As at                                          September 30, December 31,
    (in thousands of U.S.$)                                2007         2006
    -------------------------------------------------------------------------
    ASSETS
    Cash and short-term investments                      98,720      108,617
    Accounts receivable                                  24,876       25,231
    Inventories                                          35,149       33,619
    Deferred income taxes                                11,363        5,372
    Other current assets                                  6,504        6,303
    Assets from discontinued operations                       -        2,365
    -------------------------------------------------------------------------
    Total current assets                                176,612      181,507
    -------------------------------------------------------------------------
    Long-term investments                                32,478       53,840
    Property and equipment, net                          57,533       59,783
    Intangible assets, net                              229,409      244,954
    Goodwill                                            641,943      630,770
    Deferred income taxes                                 6,748        4,804
    Deferred financing costs                             14,159       14,845
    Other assets                                            678          255
    Assets from discontinued operations                       -       15,116
    -------------------------------------------------------------------------
    Total assets                                      1,159,560    1,205,874
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES AND SHAREHOLDERS' EQUITY
    Current liabilities                                  77,886       67,950
    Liabilities from discontinued operations                  -        4,226
    Long-term debt                                      575,000      575,000
    Deferred income taxes                                48,164       71,813
    Other tax liabilities                                 5,908            -
    Other long-term liabilities                           4,116        4,052
    Stockholders' equity                                448,486      482,833
    -------------------------------------------------------------------------
    Total liabilities and stockholders' equity        1,159,560    1,205,874
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    

    Forward Looking Statements
    --------------------------
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or the failure
to comply with, governmental regulations; adverse results or unexpected delays
in drug discovery and clinical development processes; decisions, and the
timing of decisions, made by health regulatory agencies regarding approval of
our technology and products; the requirement for substantial funding to
conduct research and development and to expand commercialization activities or
consummate acquisitions; sales numbers and future guidance publicly provided
by Boston Scientific Corporation regarding sales of their paclitaxel-eluting
coronary stent products; and any other factors that may affect performance. In
addition, our business is subject to certain operating risks that may cause
the actual results expressed or implied by the forward-looking statements in
this report to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete preclinical and clinical development of our
products; changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection resulting
from third party challenges to our patents; commercialization limitations
imposed by patents owned or controlled by third parties; our ability to obtain
rights to technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce timely patent
and other intellectual property protection for our technology and products;
the ability to enter into, and to maintain, corporate alliances relating to
the development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the ability of Boston Scientific
Corporation to successfully manufacture, market and sell their
paclitaxel-eluting coronary stent products; the continued availability of
capital to finance our activities; our ability to continue to integrate into
our business the operations of American Medical Instruments Holdings, Inc.
("AMI"); our ability to achieve the operational and other synergies and the
other commercial or financial benefits expected as a result of the acquisition
of AMI; and any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory authorities
or the SEC. Given these uncertainties, assumptions and risk factors, readers
are cautioned not to place undue reliance on such forward-looking statements.
We disclaim any obligation to update any such factors or to publicly announce
the result of any revisions to any of the forward-looking statements contained
in this press release to reflect future results, events or developments.

    Quill(TM) is a trademark of Quill Medical, Inc., a wholly-owned
    subsidiary of Angiotech Pharmaceuticals, Inc.

    HemoStream(TM) is a trademark of Rex Medical, LP, used under license by
    Angiotech.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX, ANP)
please visit our website at www.angiotech.com.





For further information:

For further information: Media: Jodi Regts, Senior Manager, Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,
jregts@angio.com; Analysts and Investors: Deirdre Neary, Manager, Investor
Relations, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890